Global CAR T-cell Therapy Market Outlook to 2022: The Leading Players are Bluebird Bio, CARsgen Therapeutics, Celgene, Gilead, and Novartis - ResearchAndMarkets.com

October 9, 2018

DUBLIN--(BUSINESS WIRE)--Oct 9, 2018--The “Global CAR T-cell Therapy Market 2018-2022” report has been added to ResearchAndMarkets.com’s offering.

The Global CAR T-cell Therapy Market is anticipated to grow at a CAGR of 63.15% during the period 2018-2022.

The report has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

One trend affecting this market is the collaborative R&D efforts. In the past few years, the market has witnessed several research institutions, biotechnology companies, and pharmaceutical players collaborating for the research of CAR T-cell therapies.

According to the report, one driver influencing this market is the proven effectiveness of CAR T-cell therapy. CAR T-cell therapies are proven to have higher efficacy than the other therapies that are currently available in the market for treatment of cancer.

Further, the report states that one challenge affecting this market is the high cost of CAR T-cell therapy. The high costs associated with CAR T-cell therapy is one of the biggest challenge for the growth of the market.

Market Trends

Collaborative R&D Efforts Reimbursement Coverage Advent of Armored CAR T-cells

Key Vendors

Bluebird Bio CARsgen Therapeutics Celgene Gilead Novartis

Key Topics Covered

1. Executive Summary

2. Scope of the Report

3. Research Methodology

4. Market Landscape

5. Market Sizing

6. Five Forces Analysis

7. Pipeline

8. Market Segmentation by Antigen

9. Customer Landscape

10. Regional Landscape

11. Decision Framework

12. Drivers and Challenges

13. Market Trends

14. Vendor Landscape

15. Vendor Analysis

For more information about this report visit https://www.researchandmarkets.com/research/446nbx/global_car_tcell?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20181009005687/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager


For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Genomics,Oncology Drugs



SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 10/09/2018 08:56 AM/DISC: 10/09/2018 08:56 AM


Update hourly